Mylan/Biocon’s Insulin Glargine Has Narrow Window For Approval In US

 
• By Sue Sutter
  
running-out-of-time-concept
Time is running out on Mylan’s application for insulin glargine. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Biosimilars & Generics